Why I Passed on ABVX

Welcome to The Options Desk. This is a new series where I walk through real trades I am evaluating, in real time, using the tools on the Wealth Engine Pro platform. Some of these trades I will take. Most of them I will not. The point is not the outcome. The point is the process: how to use the scanner, how to read the data, and how to know when to walk away. If you sell options for income, this series is for you.

The Scan

I run the Put Option Scanner most mornings. The setup I use filters for weekly contracts expiring within seven days, with strikes between $100 and $158, and next earnings dates after expiration. That last filter is important: I do not want to sell premium into an earnings announcement. The scanner sorts by return on capital, descending, so the fattest premiums show up first.

This morning, the top of the list was dominated by two names. Futu Holdings (FUTU) appeared multiple times across different strikes, which is common for high-IV names. But the second entry caught my attention: Abivax SA (ABVX), trading at $124.03, with a $122 strike weekly put paying $7.40 in premium. The capital requirement for a cash-secured put at that strike is $12,200.

That is a 6.07% return on capital in seven days. Annualized, it works out to roughly 316%. For context, the scanner's beat-the-index benchmarks show the S&P 500 at 20.7% annualized, the Nasdaq 100 at 25.8%, and the platform average across all symbols at 33.9%. A 316% annualized return is not a normal number. The scanner is telling you something, and what it is telling you is: something is going on with this stock.

I did not recognize the name. That is not unusual. The scanner covers thousands of contracts across the full universe of tracked stocks and ETFs. When a name I do not recognize is paying premium that far above the benchmarks, the next step is always the same: click into the stock page and read the news.

The Dig

Abivax is a clinical-stage biotech based in France and the United States. Their lead drug candidate, obefazimod, is an oral treatment for ulcerative colitis. It is a first-in-class miR-124 enhancer, which sounds like a lot of jargon but the short version is: if it works at scale, it would be a meaningful new option for a disease that currently relies on biologics that are expensive, injectable, and often lose effectiveness over time. An oral alternative that holds up long-term would be a big deal.

Here is where it gets interesting. The news feed on the platform surfaced a stack of catalysts that explain exactly why the premium is so elevated.

The Phase 3 Readout

The 44-week maintenance data from the Phase 3 ABTECT program is expected in late Q2 2026. That is now. The 8-week induction trials already came back positive in July 2025: the 50mg dose hit its primary endpoint for clinical remission with a pooled 16.4% treatment difference over placebo. The company enrolled 1,275 patients across 600+ sites in 36 countries. This is not a small trial.

The maintenance readout is the second half of the story. If the drug holds up over 44 weeks, Abivax plans to file a New Drug Application with the FDA in the second half of 2026. If it does not, the entire thesis collapses. There is no in-between. This is the definition of a binary catalyst.

The Takeover Speculation

In March 2026, French publication La Lettre reported that Abivax had granted AstraZeneca exclusive access to confidential information until March 23 to formalize a takeover bid. The stock surged 17% on the report. Then Abivax denied it, calling the claims unfounded rumors. AstraZeneca declined to comment. The stock gave back most of the gain.

Earlier, in January, the CEO had denied a separate La Lettre report that Eli Lilly was an acquisition target. Two denied takeover reports from the same French outlet in three months. The market is pricing in the possibility that where there is this much smoke, there might eventually be fire, especially after the Phase 3 data drops. Analysts have noted that any bidding process would more likely begin after the maintenance readout, which means the takeover speculation and the clinical data are stacked on top of each other as catalysts.

The Capital Activity

On May 5, Abivax repurchased $90 million in royalty certificates from early investors and priced a $45 million ADS offering at $111.57 per share. Half the repurchase was paid in cash, half through shares issued to the selling shareholders. That is a dual signal: management is confident enough to simplify the capital structure, but the share issuance added dilution. Cash runway extends into Q4 2027, so this is not a company running out of money. It is a company positioning for commercialization.

The Put Flow

There is one more piece. Bearish put volume on ABVX was flagged as heavy and directionally bearish back on May 12. I am not the only person looking at this premium. That bearish flow is itself contributing to the IV inflation, which means the elevated premium I see on the scanner is partly a reflection of other traders already positioning for downside. When smart money is buying puts at these levels, selling those same puts requires a very specific reason to believe they are wrong.

The Pass

The premium is high for a reason. Every one of those catalysts, the Phase 3 readout, the takeover speculation, the recent dilution, the heavy put flow, is the market telling you that this stock can move 30% to 50% in either direction within weeks. If the maintenance data is positive, the stock probably gaps up on FDA filing expectations and renewed takeover chatter. If the data disappoints or is mixed, you are looking at a clinical-stage biotech with no approved product, no revenue, and a stock price that just lost its primary catalyst. The gap down in that scenario could be severe.

Selling a cash-secured put at the $122 strike means I am committing $12,200 to own this stock if it drops below that level. The $7.40 in premium gives me a cost basis of $114.60. In a scenario where the Phase 3 readout fails, this stock is not going to $114. It is going to $60 or $70 or lower. The premium does not come close to covering that kind of move.

This is the core discipline of selling puts for income: the premium has to compensate you for the risk of owning the stock. When the premium is elevated because of a known binary event, the question is not whether the return looks good on an annualized basis. The question is whether you would be comfortable owning 100 shares at your cost basis if the worst-case scenario plays out. For a pre-revenue biotech with a single drug candidate and a readout due any day, the answer for me is no.

The scanner did its job. It surfaced a trade with exceptional premium. The news page did its job. It explained why that premium exists. And the data made the decision straightforward. There are plenty of ways to generate income selling puts on companies with real revenue, real earnings, and catalysts that do not involve a coin-flip clinical outcome. I will be here next week looking at the next one.

That is the philosophy behind the Wealth Engine Pro platform: let the data lead, not the premium, not the narrative, not the fear of missing out. The tools surface the opportunity. The research reveals the risk. And the discipline is knowing which trades to skip.